Reporter: Aviva Lev-Ari, PhD, RN
Immunomodulatory Therapeutic Antibodies for Cancer
http://www.immunotherapiescongress.com/Conferences_Overview.aspx?id=124174
ImmunotherapiesCongress.com
August 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MA Final Agenda
Register by May 17 and Save up to $300!
Organized by:
Cambridge Healthtech Institute
Inaugural Immunomodulator Antibodies for Cancer
August 14-15
Inaugural Emerging Cancer Immunotherapies and Vaccines
August 13-14
Sessions Include:
• Cancer Biology and Biomarkers
• Emerging Cancer
Immunotherapies & Vaccines
• Clinical Development of
Immunomodulatory Antibodies
• Bispecific Immunomodulatory
Antibodies
Keynote Presentations:
The Promise of T-Cell Engineering
Michel Sadelain, M.D., Ph.D., Director, Center
for Cell Engineering & Gene Transfer and
Gene Expression Laboratory, Memorial Sloan-
Kettering Cancer Center
Immune Monitoring on
Pre-Surgical Clinical Trials with
a Novel Checkpoint Blockade
Agent, Anti-CTLA-4
Padmanee Sharma, M.D., Associate Professor,
Genitourinary Medical Oncology, University of
Texas MD Anderson Cancer Center
Co-Located Event
Eighth Annual
Novel Vaccines:
Innovations & Adjuvants
To Advance the Science of Vaccines
Immuno The
Congress
herapies Immune System Modulation
for Novel Cancer Treatments
ImmunotherapiesCongress.com
Short Courses:
Melanoma Biology and Immunotherapies
Monday, August 12
Manufacturing Vaccines:
New Approaches, New Technologies
Wednesday, August 14
ImmunotherapiesCongress.com 2
Pre-Conference Short Course *
Monday, August 12 • 2:00-5:00PM
Melanoma Biology and
Immunotherapies
Significant advances have been made in the understanding of the molecular
underpinnings of melanoma development and progression and in elucidating
the mechanisms by which these tumors escape immune surveillance. This
session will address the current understanding of somatic genetic alterations
that serve as the fundamental building blocks for malignant transformation
in melanoma and as the basis for the first generation of molecular targeted
therapies. Immune recognition of melanoma has been long recognized and
underlies melanoma’s relatively unique responsiveness to cytokine-based
immunotherapy. However, understanding of the negative immunomodulatory
regulators that prevent elimination of melanoma has led to novel therapeutic
approaches that manipulate effector antitumor T cell function.
Instructors:
Keith T. Flaherty, M.D., Associate Professor, Department of Medicine, Harvard Medical
School; Director, Termeer Center for Targeted Therapy, Cancer Center, Massachusetts
General Hospital
Jennifer Wargo, M.D., Surgical Oncologist, Massachusetts General Hospital; Instructor,
Harvard Medical School
Dinner Short Course*
Wednesday, August 14 • 6:30-9:30pm
Manufacturing Vaccines:
New Approaches, New Technologies
Novel vaccine production platforms are changing vaccines, affecting efficacy,
and steering manufacturing away from egg-based production. This course will
look at how vaccine production is being innovated, and how these innovations
are affecting the way vaccines work. New technologies, such as cell culturebased
production and using the BEVS (Baculovirus Expression Vector System),
are opening the door to improved vaccines. Join us for this intimate discussion
of how vaccine production is being revolutionized.
Instructors:
Sue Behrens, Ph.D., Consultant, Biologic, Vaccine & Sterile Products Manufacturing
Technology, SB Executive Consulting, LLC (former Senior Director of Biological Sciences
& Strategy, Vaccine & Sterile Operations at Merck)
Todd Talarico, Ph.D., Vice President, Manufacturing, Medicago-USA
*Separate registration required
Conference Hotel:
Hilton Boston Back Bay Hotel
40 Dalton Street
Boston, MA 02115
Phone: 617-236-1100
Discounted Room Rate: $195 s/d
Discounted Room Rate Cut-off Date: July 15, 2013
Please visit our conference website to make your
reservations online or call the hotel directly to
reserve your sleeping accommodations. Identify
yourself as a Cambridge Healthtech Institute
conference attendee to receive the reduced room
rate. Reservations made after the cut-off date
or after the group room block has been filled
(whichever comes first) will be accepted on a
space- and rate-availability basis. Rooms are
limited, so please book early.
HOTEL & TRAVEL INFORMATION
Flight Discounts:
To receive a 5% or greater discount on all American Airline flights please use one of the following
methods:
• Call 1-800-433-1790 use Conference code (8283BJ)
• Go online http://www.aa.com enter Conference code (8283BJ) in promotion
discount box
• Contact Rona Meizler, Great International Travel 1-617-559-3735
Car Rental Discounts:
Special discount rentals have been established with Hertz for this conference. Please use one of the
following methods:
• Call HERTZ, 800-654-3131 use our Hertz Convention Number (CV): 04KL0002
• Go online http://www.hertz.com use our Hertz Convention Number (CV): 04KL0002
3 ImmunotherapiesCongress.com
Inaugural
Emerging Cancer Immunotherapies and Vaccines
Next-Generation Targets and Strategies
August 13-14
Using lessons learned from early cancer vaccines and immunotherapeutics, a new wave of programs are underway that promise improved efficacy and
safety over a wider range of cancers. Emerging Cancer Immunotherapies and Vaccines will examine new targets and strategies in this space, along with
important studies in preclinical development associated with developing these programs into successful drug products. Speakers will offer approaches to
resolve the most challenging steps in the transition of these programs from research into clinical development.
TUESDAY , AUGUST 13, 2013
7:30 am Main Conference Registration and Morning Coffee
8:05 Chairperson’s Opening Remarks
T Cell Immunotherapy Strategies
»»8:15 Op ening Keynote Presentation
The Promise of T Cell Engineering
Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering & Gene Transfer and
Gene Expression Laboratory, Memorial Sloan-Kettering Cancer Center
T cell engineering offers a unique means to overcome the immune escape
stratagems used by tumors to elude immune rejection. The genetic
reprogramming of patient T cells can thus be used to enforce tumor
recognition, improve T cell survival, augment T cell expansion, generate
memory lymphocytes and offset T cell anergy and immune suppression.
Using “second-generation chimeric antigen receptors” (CARs), recent clinical
studies support the merit of this novel immunotherapy.
9:00 It Takes Two to Tango: Fine Tuning of Tumor Cells and T
Lymphocytes for Maximized Anti-Tumor Activity
Daniel J. Powell, Jr., M.D., Assistant Professor, Pathology and Laboratory Medicine, Perelman
School of Medicine, University of Pennsylvania
Genetic engineering with chimeric immune receptors now allows for rapid
de novo generation of autologous T cells with potent anti-tumor activity for
adoptive cell transfer therapy for cancer. Still, low target antigen expression
by tumor cells and antigen expression on normal tissues may render therapy
ineffective or potentially toxic. We have identified agents that sensitize tumor
cells to immune attack and made advances in T cell engineering strategies to
better direct T cells to tumor antigen and confine T cell activity to tumor.
9:30 Improved Cancer Immunotherapy through CD134 plus
CD137 Dual Co-Stimulation
Adam J. Adler, Ph.D., Associate Professor of Immunology, University of Connecticut
T cell-mediated anti-tumor immunity is dampened by tolerance mechanisms
that evolved to prevent autoimmunity. Since tolerance largely results as
a consequence of insufficient co-stimulation during antigenic priming, costimulatory
receptor agonists can program tumor-specific T cell expansion and
effector differentiation. In particular, dual administration of agonists to CD134 plus
CD137 activates multiple immune cells with tumoricidal potential including NK
cells, cytotoxic CD8+ T cells, and surprisingly, cytotoxic CD4+ T cells.
10:00 Refreshment Break
Cancer Biology and Biomarkers
10:30 Vascular Normalization as an Emerging Strategy to
Enhance Cancer Immunotherapy
Rakesh K. Jain, Ph.D., Andrew Werk Cook Professor of Tumor Biology, Harvard Medical
School; Director, E.L. Steele Laboratory of Tumor Biology, Department of Radiation Oncology,
Massachusetts General Hospital
The immunosuppressive tumor microenvironment remains a limiting factor
for anti-cancer vaccine therapies. In addition, tumors systemically alter
immune cells’ function via secretion of cytokines such as VEGF, a major proangiogenic
cytokine. Hence, anti-angiogenic treatment may be an effective
modality to potentiate immunotherapy. I will discuss the effects of VEGF
on anti-tumor immune responses, and propose a potentially translatable
strategy to re-engineer the tumor immune microenvironment and improve
cancer immunotherapy.
11:00 Advances in Biomarker Validation and Trial Design for
Antitumor Immunotherapy
Susan R. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Sidney Kimmel Center for Prostate
and Urologic Cancers, Memorial Sloan–Kettering Cancer Center
Conventional imaging modalities have been the mainstay of assessing
treatment response. Recent data suggests that evaluating circulating tumor
cells may provide insight regarding changes in the tumor cells’ overall
behavior. Immunologic treatments often do not impact the cancer with
immediacy; a means of determining whether an immunologic target is hit
and whether it impacts the tumor’s biology remains a challenge. Changes in
T cell populations or myeloid suppressor cells may reflect potential impact on
the intra- and extra-tumoral milieu.
11:30 Exploring Synergy between Targeted Therapy and
Immunotherapy
Zachary Cooper, Ph.D., Postdoctoral Research Associate, Surgical Oncology, Massachusetts
General Hospital
Recent advances in the treatment of melanoma include the use of BRAFtargeted
therapy and immune checkpoint inhibitors, though each of
these treatments alone has its limitation. There is increasing evidence
for synergy between these modalities. Treatment with a BRAF inhibitor
results in enhanced melanoma antigen expression and a more favorable
microenvironment. Exploring the potential synergy using mouse models is
necessary in overcoming monotherapy limitations.
12:00pm Sponsored Presentations (Opportunities Available:
Contact Suzanne Carroll at 781-972-5452 or scarroll@healthtech.com
for more information)
12:30 Luncheon Presentation (Opportunity Available)
or Lunch on Your Own
Emerging Cancer Immunotherapies
1:55 Chairperson’s Opening Remarks
2:00 Synergism Between Anti-Tumor Antibodies and PKExtended
IL-2
K. Dane Wittrup, Ph.D., Dubbs Professor, Chemical Engineering and Biological Engineering, Koch
Institute for Integrative Cancer Research, Massachusetts Institute of Technology
We have found that combination treatment with anti-tumor antibody and an
IL-2 Fc fusion exerts a significantly stronger suppression of tumor growth
than either agent alone. This effect depends on the presence of both CD8+
T cells and neutrophils, indicating a close cooperation between innate and
cellular immunity. Strong potential exists for further synergy between antitumor
antibodies and the new generation of T cell-directed immunotherapies.
ImmunotherapiesCongress.com 4
2:30 Identifying New Cancer Immunotherapy Targets for T Cells
Robert Holt, Ph.D., Senior Scientist and Head of Sequencing, British Columbia Cancer Agency,
Canada
Effective cancer immunotherapy relies on effective tumor antigens. However,
most variations that distinguish tumor cells from normal cells are sporadic,
and their immunogenicity is undetermined. High throughput genomic
analysis is a useful approach for evaluating the potential immunogenicity
of individual tumors and identifying new candidate antigens for follow-on
validation. We are using two methods for T cell antigen discovery that will be
described, including tumor genome sequencing and computational epitope
prediction, plus deep TCR sequencing of tumor-associated T cells.
3:00 Immunomodulatory Antibody-Fusion Proteins for Cancer
Immunotherapy
Dafne Müller, Ph.D., Researcher, Institute of Cell Biology and Immunology, University of Stuttgart,
Germany
Cytokines of the common cytokine receptor γ-chain family and costimulatory
members of the B7- and TNF-family have shown great potential
to support the generation and development of an antitumor immune
response. In order to improve the efficacy of such molecules at the tumor
site we designed antibody fusion proteins for therapeutic approaches,
focusing either on optimized presentation or a combined mode of action.
3:30 Refreshment Break
4:00 TIM (T Cell Immunoglobulin and Mucin)-3 as a Potential
Target for Cancer Immunotherapy
Ana Carrizosa Anderson, Ph.D., Assistant Professor, Neurology, Harvard Medical School
TIM-3 marks both “exhausted” CD8+ T cells and regulatory T cells (Treg) present
in solid tumors. TIM-3/PD-1 co-blockade down-modulates Treg suppressor
function in Tim-3+ Treg, restores function to exhausted CD8+ T cells, and is highly
effective in controlling tumor growth. Thus, TIM-3/PD-1 blockade down-modulates
two major mechanisms of immune suppression that are active in tumor-bearing
hosts, namely exhausted CD8+ T cells and Treg.
4:30 Allovectin: In vivo Studies and Potential Synergy with
other Advanced Melanoma Immunotherapeutics
John Doukas, Ph.D., Senior Director, Preclinical Safety and Efficacy, Vical, Inc.
Allovectin® is a cancer immunotherapeutic currently completing
evaluation in a pivotal Phase 3 metastatic melanoma study. Designed
for direct intratumoral administration, it is intended to induce antitumor
immune responses against both treated and distal lesions by stimulating
innate and adaptive immune responses. This presentation will review
Allovectin’s proposed mechanisms of action and potential synergy with
other immunotherapies, drawing supporting data from preclinical and
clinical studies.
5:00 Clinical Update of IL2 Adjunctive Co-Therapy for
Suppression of Solid Tumors with Designer T Cells
Richard P. Junghans, M.D., Professor, Department of Medicine, Boston University School of
Medicine; Roger Williams Medical Center
IL2, an essential adjunct in therapies with tumor-infiltrating lymphocytes, has
not been widely applied in designer T cell interventions, although rationales
for supplementation would seem to bridge both settings. This discrepancy
may reflect the restricted set of investigators with IL2 experience rather than
a biologically motivated choice. Preclinical data establishesthe need for IL2
to eliminate established tumors with dTc, and early clinical data in prostate
cancer targeting may be interpreted similarly.
5:30-6:30 Reception in Exhibit Hall with Poster Viewing
WEDNESDAY , AUGUST 14, 2013
8:55am Chairperson’s Opening Remarks
Emerging Cancer Vaccines
9:00 Challenges in Vaccine Therapy for Hematological
Malignancies
David E. Avigan, M.D., Associate Professor, Medicine, Harvard Medical School; Director,
Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical
Center
We have developed a tumor vaccine in which patient-derived tumor cells
are fused with autologous dendritic cells. We have demonstrated that
vaccination during post-transplant lymphopoietic reconstitution results in the
significant expansion of myeloma-specific T cells. We are now integrating
vaccination with reversing critical elements of tumor-mediated immune
suppression. This includes vaccination in the context of blockade of the
PD-1/PDL-1 pathway.
9:30 Biomarkers Correlative of Clinical Response to Sipuleucel-T
James Trager, Ph.D., Vice President, Research, Dendreon
Sipuleucel-T is an autologous cellular immunotherapy approved in the
United States for the treatment of asymptomatic or minimally symptomatic
metastatic castrate resistant prostate cancer. A variety of biomarkers,
both baseline and pharmacodynamic, are correlative of clinical response to
sipuleucel-T. We will discuss the biological interpretations of these markers
and in particular their implications in understanding the mechanism of action
for sipuleucel-T.
10:00 Partnering Therapeutic Vaccines with Large Pharma
Kevin Heller, Global Lead Oncology; Search, Evaluation and Diligence, Bristol-Myers Squibb
10:30 Refreshment Break in Exhibit Hall with Poster Viewing
11:15 Clinical Results of Pexa-Vec (JX-594): Multi-Mechanistic
Oncolytic Viruses as a Strategy for Cancer Immunotherapy
Anne Moon, Ph.D., Vice President, Product Development, Jennerex
Oncolytic immunotherapy is an emerging therapeutic approach designed
to induce acute tumor debulking as well as chronic suppression of tumor
outgrowth. Pexa-Vec (JX-594) is an oncolytic vaccinia virus engineered for
enhanced cancer targeting and immune stimulation. Recent preclinical and
clinical results demonstrate a multi-pronged MOA, including induction of
tumor-specific immunity, demonstrating the potential for Pexa-Vec to serve
as an active immunotherapy that is “personalized” yet “off-the-shelf.”
11:45 Clinical Update on PROSTVAC, a Therapeutic Vaccine
Candidate for Advanced Prostate Cancer
Alain Delcayre, Ph.D., Vice President, R&D, BN Immunotherapeutics
PROSTVAC® is a candidate cancer vaccine that demonstrated a statistically
significant overall survival benefit while displaying a favorable side effect
profile in patients with asymptomatic-to-minimally-symptomatic metastatic
castrate-resistant prostate cancer in a randomized, placebo-controlled Phase
II trial. A Phase III clinical trial is underway to confirm clinical benefit, as well
as expand our understanding of immune responses to cancer vaccines.
12:15 pm Close of Conference
Sponsoring Pubs
5 ImmunotherapiesCongress.com
The recent approval of BMS’s Yervoy (ipilumumab) and a succession of related programs advancing through clinical trials has generated increased interest
in the development of antibody-based immunomodulators for cancer. Immunomodulatory Therapeutic Antibodies for Cancer will provide updates of
clinical stage programs, and examine how these novel therapeutics influence trial design and the selection of clinical endpoints. Strategies for immune
modulation that are most appropriate for targeting with antibodies will be considered, along with where combination regimens and new therapeutic formats
can be effectively applied.
Inaugural
Immunomodulatory Antibodies for Cancer
Clinical Progress and Challenges in Drug Product Development
August 14-15
WEDNESDAY , AUGUST 14, 2013
1:40 pm Chairperson’s Opening Remarks
»»1:45 Keynote Presentation:
Immune Monitoring on Pre-Surgical Clinical Trials with a Novel
Checkpoint Blockade Agent, Anti-CTLA-4
Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University
of Texas MD Anderson Cancer Center
Biomarker studies for immunotherapies have typically involved monitoring
immunologic changes within the systemic circulation; however, recent
data indicates that immunological changes within tumor tissues are more
likely to predict clinical responses. We conducted a pre-surgical clinical trial
with anti-CTLA-4 (ipilimumab) in patients with localized bladder cancer, and
identified ICOS as the marker of a subset of effector T cells that is increased
in frequency after anti-CTLA-4 therapy. ICOS+ T cells are being explored
as pharmacodynamic markers for treatment with anti-CTLA-4 and as novel
targets to improve the efficacy of anti-CTLA-4 therapy.
Immune Checkpoint Blockades
2:30 Preliminary Clinical Efficacy and Safety of MK-3475
(Anti-PD-1 Monoclonal Antibody) in Patients with Advanced
Melanoma
Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
The programmed death-1 (PD-1) pathway has emerged as an important
tumor-evasion mechanism. When PD-1 and PDL-1 join together, the T cell’s
ability to target the tumor cell is disarmed. Targeting either PD-1 or PDL-1
can stimulate the immune system and enhance T cells’ ability to lyse tumor
cells. Similar to, but distinct from cytotoxic T lymphocyte antigen 4 (CTLA-4)
this pathway hold promise for many solid tumors.
3:00 Sponsored Presentations (Opportunities Available: Contact
Suzanne Carroll at 781-972-5452 or scarroll@healthtech.com for
more information)
3:30 Refreshment Break in the Exhibit Hall with Poster Viewing
4:15 Development of Immunomodulatory PD-1 Antibodies in
Renal Cell Carcinoma
Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute
Targeting the immunosuppressive PD-1 pathway is an area of intense
investigation. RCC tumor cells may innately express the ligand of PD-1 or
they may acquire it from adaptive immunity. Expression has been associated
with worse outcomes. Attempts at countering this host immune system
evasion technique are underway with a variety of monoclonal antibodies
against PD-1 and its ligands.
4:45 Anti-PD-1 Antibody Therapy for B-Cell Lymphoma
Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division
of Cancer Medicine, The University of Texas MD Anderson Cancer Center
In a phase II trial, the combination of pidilizumab, a humanized anti-PD-1
monoclonal antibody, and rituximab was active and non-toxic in patients with
relapsed follicular lymphoma. Activation of T and NK cells was observed in
both peripheral blood and tumor microenvironment after pidilizumab therapy
and predictors of clinical outcome based on the molecular features of tumorinfiltrating
immune cells at baseline were identified.
5:15 AMP-224, A Fusion Protein with Potential to Modulate
the PD-1 Pathway
Solomon Langermann, Ph.D., CSO, Amplimmune
AMP-224 is the first recombinant B7-DC-Fc fusion protein tested in patients
that binds to and modulates the PD-1 axis through a unique MOA. The
MOA hypothesis for AMP-224 is depletion of PD-1 high expressing T-cells
representing exhausted effector cells. The pharmacodynamic readouts
obtained to date demonstrate that AMP-224 is biologically active in its
target patient population. Data from the trial has been used to establish
hypotheses regarding the characteristics of patients most likely to respond
clinically to AMP-224 treatment.
5:45 Close of Sessions
THURSDAY , AUGUST 15, 2013
Emerging Targets
8:25 am Chairperson’s Opening Remarks
8:30 Immunocytokines: A Novel Potent Class of Armed Antibodies
Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
The severe toxicity of recombinant cytokines even at low doses limits
their therapeutic potential, but this can be mitigated by using monoclonal
antibodies to target their delivery. This talk will cover the latest advanced
preclinical and clinical data of the Philogen group, detailing the discovery and
development of armed antibodies against angiogenesis-specific markers,
which are attractive targets relevant to many angioproliferative diseases.
9:00 Mechanism of Action and Progress Update for MGA271:
An Fc-Enhanced mAb Targeting B7-H3 in Solid Tumors
Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
Characterization of murine monoclonal antibodies generated from cancer
cell and/or stem cell-based immunizations identified a panel targeting the
immunoregulatory protein B7-H3 displaying broad tumor reactivity but
limited binding to normal tissue. Preclinical evaluation of MGA271, an Fcenhanced
anti-B7H3 mAb, revealed strong ADCC activity against a broad
range of tumor cell types, potent antitumor activity in xenograft models
employing human FcR transgenic mice and a favorable safety profile in nonhuman
primate toxicology studies. A phase I/IIa clinical study of MGA271
in patients with B7-H3-positive metastatic or recurrent adenocarcinoma is
currently recruiting patients.
ImmunotherapiesCongress.com 6
9:30 Preclinical Update: Development of a Human Anti-CD27
Monoclonal Antibody as a Potential Cancer Therapy
Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and
Development, Celldex Therapeutics, Inc.
Agonist antibodies binding the co-stimulatory molecule CD27 have potent
antitumor activity in murine tumor models through boosting of durable T
cell antitumor immunity. Anti-CD27 antibodies have also been shown to
mediate the direct killing of CD27-expressing tumors. Such preclinical data
supports the therapeutic potential of this anti-CD27 monoclonal antibody as
a cancer immunotherapy.
10:00 Sponsored Presentation (Opportunity Available)
10:15 Refreshment Break in the Exhibit Hall with Poster Viewing
11:00 Targeting CD47-SIRPα Interactions for Potentiating
Antibody Therapy in Cancer
Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin Blood Supply Foundation,
The Netherlands
We will present findings demonstrating that interactions between CD47
expressed on cancer cells and the myeloid inhibitory immunoreceptor SIRPα
form a barrier for the antibody-mediated destruction of cancer cells. These
findings identify the CD47-SIRPα interaction as a potential generic target for
improving the efficacy of cancer antibody therapeutics.
11:30 Presentation to be Announced
12:00 Sponsored Presentations (Opportunities Available)
12:30 Luncheon Presentation (Opportunity Available)
or Lunch on Your Own
Clinical Development of
Immunomodulatory Antibodies
1:55 Chairperson’s Opening Remarks
2:00 Clinical Trials Design for Cancer Immune Therapies
Harriet Kluger M.D., Associate Professor, Yale Cancer Center
Clinical development of immune therapies is challenging; standard drug
development paradigms are often not applicable. Modifications are
necessary in regard to dose escalation, management and definition of
toxicities, within-patient dose reduction, and radiographic assessment of
response to therapy. In later stage trials new definitions of study endpoints
are needed. Correlative biomarker studies are complex, and require
assessment of baseline immune function and tumor characteristics.
2:30 Characteristics and Management of Immune-Related
Adverse Effects Associated with Ipilimumab, a New
Immunotherapy for Metastatic Melanoma
Stephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center
Immune-Related Adverse Effects are a new phenomenon related to
advances in the use of the first FDA approved monoclonal antibody
Ipilimumab for metastatic melanoma. These side effects are different
than side effects of traditional cytotoxic regimens. These immunemediated
side effects include enterocolitis, hepatitis, dermatitis,
neuropathy andendocrinopathy.
Bispecific Immunomodulatory Antibodies
3:00 Safety Challenges to Development of Immune System
Activating Antibodies
Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics
Safety Assessment, Pathology & LAR, MedImmune (AstraZeneca Biologics)
Immune system activating antibodies with abilities to harness and enhance
an individual patient’s immune system and target tumors are revolutionizing
the treatment of many deadly cancers. However, many immune-activating
biologics have serious dose-limiting toxicities, including cytokine stormassociated
critical toxicities and serious autoimmune diseases in multiple
key organs that may limit their long-term use. Nonclinical and clinical safety
challenges and risk mitigation opportunities will be discussed in the context
of immune activating antibodies, including bispecific BiTE antibodies.
3:30 Refreshment Break
3:45 MCLA-117: ABiclonics – ENGAGE Bispecific IgG Product
Lead Targeting CLEC12A and CD3 in AML
Lex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands
MCLA-117, a common light chain T cell-engaging full-length human bispecific
antibody (Biclonics – ENGAGE) was discovered that targets CD3 on T cells
and CLEC12A on acute myeloid leukemia (AML) blasts and leukemic stem
cells. Co-incubation of resting patient T cells and AML cells with MCLA-
117 results in efficient tumor cell lysis. Clinical application of MCLA-117
potentially provides a therapy in AML that more efficiently eradicates the
cancer cells and prevents relapse.
4:15 Bispecific Antibody Targeting CD47 Aiming at Increasing
Phagocytosis of Cancer Cells
Krzysztof Masternak, Ph.D., Head of Biology, Novimmune SA, Switzerland
CD47 is a ubiquitously expressed transmembrane receptor with multiple
functions in cell-to-cell communication. Its interaction with SIRPα expressed
in macrophages and DCs inhibits their phagocytic function. Overexpression
of CD47 in cancer cells is often observed and it is believed to help cancer
cells escape immune surveillance. We have generated bispecific antibodies
(BsAbs) that preferentially neutralize CD47-SIRPα interaction on cancer cells.
4:45 Close of Conference
7 ImmunotherapiesCongress.com
CHI offers comprehensive sponsorship packages which include presentation
opportunities, exhibit space and branding, as well as the use of the pre and
post-show delegate lists. Customizable sponsorship packages allow you to
achieve your objectives before, during, and long after the event. Signing on
early will allow you to maximize exposure to hard-to-reach decision makers!
Agenda Presentations
Showcase your solutions to a guaranteed, highly-targeted audience. Package
includes a 15 or 30-minute podium presentation within the scientific agenda, exhibit
space, on-site branding, and access to cooperative marketing efforts by CHI.
Breakfast & Luncheon Presentations
Opportunity includes a 30-minute podium presentation. Boxed lunches are
delivered into the main session room, which guarantees audience attendance
and participation. A limited number of presentations are available for
sponsorship and they will sell out quickly. Sign on early to secure your talk!
Invitation-Only VIP Dinner/Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration
list for an evening of networking at the hotel or at a choice local venue. CHI
will extend invitations and deliver prospects. Evening will be customized
according to sponsor’s objectives:
• Purely social
• Focus group
• Reception style
• Plated dinner with specific conversation focus
Exhibit
Exhibitors will enjoy facilitated networking opportunities with high-level
conference delegates. Speak face-to-face with prospective clients and
showcase your latest product, service, or solution.
*Inquire about additional branding opportunities!
Looking for aditional ways to drive
leads to your sales team?
CHI can help!
We offer clients numerous options for custom lead generation programs to
address their marketing and sales needs, including:
Custom Lead Generation Programs:
• Targeted campaign promotion to unparalleled database of
800,000+ individuals in the life sciences
• Experienced marketing team promotes campaign, increasing
awareness and leads
Live Webinars:
• Assistance in procuring speakers
• Experienced moderators
• Dedicated operations team to coordinate all efforts
White Papers:
• Industry recognized authors, with vast editorial experience, available
to help write your white paper
CHI also offers market surveys, podcasts, and more!
To customize your participation at this event, please contact:
Suzanne Carroll – Senior Business Development Manager
781-972-5452 | scarroll@healthtech.com
Sponsorship, Exhibit, and Lead Generation Opportunities
Co-Located Event
August 13-15, 2013 • Hilton Boston Back Bay Hotel • Boston, MA
Eighth Annual
Novel Vaccines:
Innovations & Adjuvants
To Advance the Science of Vaccines
Additional registration details
Each registration includes all conference
sessions, posters and exhibits, food
functions, and access to the conference
proceedings link.
Handicapped Equal Access: In accordance
with the ADA, Cambridge Healthtech
Institute is pleased to arrange special
accommodations for attendees with
special needs. All requests for such
assistance must be submitted in writing
to CHI at least 30 days prior to the start
of the meeting.
To view our Substitutions/
Cancellations Policy, go to
http://www.healthtech.com/regdetails
Video and or audio recording of any kind
is prohibited onsite at all CHI events.
Receive a FREE eNewsletter by signing up
at chimediagroup.com
The latest industry news, commentary
and highlights from Bio-IT World
Innovative management in clinical trials
A series of diverse reports designed to
keep life science professionals informed
of the salient trends in pharmaceutical
technology, business, clinical development,
and therapeutic disease markets.
For a detailed list of reports, visit
InsightPharmaReports.com, or contact
Rose LaRaia, rlaraia@healthtech.com,
+1-781-972-5444.
Barnett is a recognized leader in clinical
education, training, and reference guides
for life science professionals involved in
the drug development process. For more
information, visit barnettinternational.com.
Cambridge Healthtech Associates™
(CHA™) leverages its extensive network
and unique collaborative model in
consulting, technology evaluations
and community-based communication
services to help clients in the life
sciences industry commercialize and
penetrate the marketplace to increase
revenue. Visit http://www.chacorporate.com.
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 • http://www.healthtech.com • Fax: 781-972-5425
Pricing and Registration Information
short courses
Academic, Government,
(Includes access to short courses only) Commercial H ospital-affiliated
Single Short Course $699 $399
Two Short Courses $999 $699
Monday, August 12 • 2:00-5:00pm Wednesday, August 14 • 6:30-9:30pm
Melanoma Biology and Immunotherapies Manufacturing Vaccines: New Approaches, New Technologies
3 Day Pricing • August 13-15 • Please Choose Package A or B
(Excludes short courses)
Package A – Novel Vaccines: Innovations & Adjuvants August 13-15
Early Registration Deadline until May 17, 2013 $2049 $1025
Advance Registration Deadline until July 19, 2013 $2199 $1099
Registrations after July 19, 2013 and on-site $2399 $1149
Package B – Emerging Cancer Immunotherapies and Vaccines August 13-14 + Immunomodulatory Antibodies for Cancer August 15-15
Early Registration Deadline until May 17, 2013 $2049 $1025
Advance Registration Deadline until July 19, 2013 $2199 $1099
Registrations after July 19, 2013 and on-site $2399 $1149
1.5 Day Pricing Please Choose Package C or D
(Excludes short courses)
Package C – Emerging Cancer Immunotherapies and Vaccines • August 13-14
Early Registration Deadline until May 17, 2013 $1399 $649
Advance Registration Deadline until July 19, 2013 $1599 $729
Registrations after July 19, 2013 and on-site $1799 $799
Package D – Immunomodulatory Antibodies for Cancer • August 14-15
Early Registration Deadline until May 17, 2013 $1399 $649
Advance Registration Deadline until July 19, 2013 $1599 $729
Registrations after July 19, 2013 and on-site $1799 $799
Conference Discounts
Poster Submission-Discount ($50 Off)
Poster abstracts are due by July 19, 2013. Once your registration has been fully processed, we will send an email containing a unique link allowing
you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com. *CHI reserves the
right to publish your poster title and abstract in various marketing materials and products.
Alumni Discount-Discount (SAVE 20%)
Cambridge Healthtech Institute (CHI) appreciates your past participation at the ImVacS & the Immunotherapies Congress. As a result of the great
loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 20% off the registration rate.
REGI STER 3 –
4th IS FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for
discount to apply.
Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact
David Cunningham at +1-781-972-5472
If you are unable to attend but would like to purchase the ImVacS & the Immunotherapies Congress CD for $750 (plus shipping),
please visit ImVacS.com. Massachusetts delivery will include sales tax.
How to Register: ImmunotherapiesCongress.com
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288
Please use keycode
IMT F
when registering!
(Alumni and Register 3 – 4th is free discounts cannot be combined)
Immuno The
Congress
herapies
August 13-15, 2013
Boston, MA
Immune Checkpoint Blockades
Keynote Presentation: Immune Monitoring on Pre-Surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4
Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
Biomarker studies for immunotherapies have typically involved monitoring immunologic changes within the systemic circulation; however, recent data indicates that immunological changes within tumor tissues are more likely to predict clinical responses. We conducted a pre-surgical clinical trial with anti-CTLA-4 (ipilimumab) in patients with localized bladder cancer, and identified ICOS as the marker of a subset of effector T cells that is increased in frequency after anti-CTLA-4 therapy. ICOS+ T cells are being explored as pharmacodynamic markers for treatment with anti-CTLA-4 and as novel targets to improve the efficacy of anti-CTLA-4 therapy.
Preliminary Clinical Efficacy and Safety of MK-3475 (Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Melanoma
Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
Sponsored Presentations (Opportunities Available: Contact Jason Gerardi at 781-972-5452 or jgerardi@healthtech.com for more information)
Development of Immunomodulatory PD-1 Antibodies in Renal Cell Carcinoma
Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute
Anti-PD-1 Antibody Therapy for B-Cell Lymphoma
Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
AMP-224, A Fusion Protein with Potential to Modulate the PD-1 Pathway
Solomon Langermann, Ph.D., CSO, Amplimmune
Emerging Targets
Immunocytokines: A Novel Potent Class of Armed Antibodies
Catherine Hutchinson, Ph.D., Research Scientist, Philochem, Switzerland
Mechanism of Action and Progress Update for MGA271: An Fc-Enhanced mAb Targeting B7-H3 in Solid Tumors
Paul Moore, Ph.D., Vice President, Cell Biology & Immunology, Macrogenics
Preclinical Update: Development of a Human Anti-CD27 Monoclonal Antibody as a Potential Cancer Therapy
Lawrence J. Thomas, Ph.D., DABT, CMAR, Senior Director, Preclinical Research and Development, Celldex Therapeutics, Inc.
Targeting CD47-SIRPa Interactions for Potentiating Antibody Therapy in Cancer
Timo van den Berg, Ph.D., Head, Blood Cell Research, Sanquin Blood Supply Foundation, The Netherlands
Clinical Development of Immunomodulatory Antibodies
Clinical Trials Design for Cancer Immune Therapies
Harriet Kluger M.D., Associate Professor, Yale Cancer Center
Characteristics and Management of Immune-Related Adverse Effects Associated with Ipilimumab, a New Immunotherapy for Metastatic Melanoma
Stephanie Andrews, Oncology Nurse Practitioner, Moffitt Cancer Center
Bispecific Immunomodulatory Antibodies
Safety Challenges to Development of Immune System Activating Antibodies
Rakesh Dixit, Ph.D., DABT, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Pathology & LAR, MedImmune (AstraZeneca Biologics)
MCLA-117: ABiclonics – ENGAGE Bispecific IgG Product Lead Targeting CLEC12A and CD3 in AML
Lex Bakker, Ph.D., Chief Development Officer, Merus, The Netherlands
Bispecific Antibody Targeting CD47 Aiming at Increasing Phagocytosis of Cancer Cells
Krzysztof Masternak, Ph.D., Head of Biology, Novimmune SA, Switzerland
View FInal Agenda | Pricing & Registration Details
Sponsorship & Exhibit Information
CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post show delegate list. Sponsorship allows you to achieve your objectives before, during, and long after the event. Any sponsorship can be customized to meet your company’s needs and budget. Signing on earlier will allow you to maximize exposure to hard-to-reach decision makers.
For sponsor & exhibitor information, please contact:
Jason Gerardi- Manager, Business Development
781-972-5452 | jgerardi@healthtech.com
ImmunotherapiesCongress.com/Immunomodulatory-Antibodies-Cancer
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 healthtech.com
http://www.immunotherapiescongress.com/Conferences_Overview.aspx?id=124174
Like this:
Like Loading...
Read Full Post »